# Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

> **NCT00995787** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00995787
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2010-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995787, "Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00995787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*